2 型糖尿病肥胖患者的体重减轻：远程监测加饮食组合的效果 - 主动身体控制（ABC）计划。

Weight loss in obese patients with type 2 diabetes: effects of telemonitoring plus a diet combination - the Active Body Control (ABC) Program.

机构信息

Institute of Clinical Chemistry, Otto-von-Guericke-University Magdeburg, 39120 Magdeburg, Leipziger Strasse 44, Germany.

出版信息

Diabetes Res Clin Pract. 2011 Mar;91(3):286-92. doi: 10.1016/j.diabres.2010.11.020. Epub 2010 Dec 17.

DOI:10.1016/j.diabres.2010.11.020

PMID:21168231

Abstract

AIMS

We evaluate the efficacy of the "Active Body Control (ABC) Program" for weight reduction in patients with type 2 diabetes.

METHODS

The ABC program combines telemonitoring of the physical activity with a low-calorie diet also preferring carbohydrates with low glycemic indexes. In this 6-month, randomized, clinical trial 35 patients (aged 57 ± 9 years; BMI=35.3 ± 5.7 kg/m(2)) were treated according to the ABC program and 35 control patients (aged 58 ± 7 years; BMI=34.8 ± 5.9 kg/m(2)) received standard therapy.

RESULTS

After 6 months the mean weight loss in the intervention group was 11.8 kg ± 8.0 kg. Glucose and HbA1c were lowered by respectively 1.0 mmol/l and 0.8 percentage points (p=0.000, respectively). The proportion of patients with HbA1c>7% fell from 57% to 26%. Antidiabetic drugs were discontinued in 13 patients (39%) and reduced in 14 (42%). The reduction of costs on medication per patient was € 83 in 6 months. In the control group, there were no relevant changes in body weight, laboratory values or drug treatment.

CONCLUSIONS

The ABC program effectively lowers body weight, Hb1Ac and antidiabetic drug use in patients with type 2 diabetes.

摘要

目的

我们评估“主动身体控制（ABC）计划”在 2 型糖尿病患者中减肥的疗效。

方法

ABC 计划将身体活动的远程监测与低热量饮食相结合，同时优先选择低血糖指数的碳水化合物。在这项为期 6 个月的随机临床试验中，35 名患者（年龄 57 ± 9 岁；BMI=35.3 ± 5.7 kg/m²）按照 ABC 计划进行治疗，35 名对照患者（年龄 58 ± 7 岁；BMI=34.8 ± 5.9 kg/m²）接受标准治疗。

结果

干预组 6 个月后平均体重减轻 11.8 公斤±8.0 公斤。血糖和 HbA1c 分别降低了 1.0 mmol/l 和 0.8 个百分点（p=0.000，分别）。HbA1c>7%的患者比例从 57%下降到 26%。13 名患者（39%）停止使用降糖药，14 名患者（42%）减少使用。6 个月内每位患者的药物治疗费用减少了 83 欧元。在对照组中，体重、实验室值或药物治疗均无明显变化。